Risk factors for disseminated intravascular coagulation in patients with lung cancer.

abstract：:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

journal_title：Thoracic cancer

authors： Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

更新日期：2020-09-01 00:00:00

abstract：:A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

journal_title：Thoracic cancer

authors： Dango S,Guenter J,Passlick B

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Next-generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy; however, little is known about the performance of the Oncomine Dx Target Test compared with conventional single gene tests for detecting EGFR mutations. The objective of this st...

journal_title：Thoracic cancer

authors： Sakaguchi T,Iketani A,Furuhashi K,Nakamura Y,Suzuki Y,Ito K,Fujiwara K,Nishii Y,Katsuta K,Taguchi O,Hataji O

更新日期：2020-12-12 00:00:00

abstract：BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...

journal_title：Thoracic cancer

authors： Wang L,Chen Y,Wang Y,Liu J,Wen Z,Chen H,Zhu Y,Wang J,Wan L,Li F,Song Y

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

journal_title：Thoracic cancer

authors： Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

更新日期：2020-11-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...

journal_title：Thoracic cancer

authors： Guo R,Li Y,Bie Z,Li B,Li X

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

journal_title：Thoracic cancer

authors： Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...

journal_title：Thoracic cancer

authors： Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

更新日期：2019-10-01 00:00:00

abstract：:Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...

journal_title：Thoracic cancer

authors： Masuda K,Tokito T,Azuma K,Yanagida E,Nakamura M,Naito Y,Matsuo N,Ishii H,Yamada K,Akiba J,Hoshino T

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...

journal_title：Thoracic cancer

authors： Unal OU,Oztop I,Yasar N,Urakci Z,Ozatli T,Bozkurt O,Sevinc A,Gunaydin Y,Yapar Taskoylu B,Arpaci E,Ulas A,Kodaz H,Tonyali O,Avci N,Aksoy A,Yilmaz AU

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. METH...

journal_title：Thoracic cancer

authors： Kawano D,Okamoto T,Fujishita T,Suzuki Y,Kitahara H,Shimamatsu S,Maehara Y

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical record...

journal_title：Thoracic cancer

authors： Lee KJ,Chung MP,Kim YW,Lee JH,Kim KS,Ryu JS,Lee HL,Park SW,Park CS,Uh ST,Lee YC,Park SJ,Kim KH,Jeon YJ,Choi WI,Park YB,Kim DS,Jeong SH,Lee JH,Park MS

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...

journal_title：Thoracic cancer

authors： Wang X,Jiang X,Li J,Wang J,Binang H,Shi S,Duan W,Zhao Y,Zhang Y

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

journal_title：Thoracic cancer

authors： Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

journal_title：Thoracic cancer

authors： Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

更新日期：2019-01-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

journal_title：Thoracic cancer

authors： Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

更新日期：2020-02-01 00:00:00

abstract：:A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...

journal_title：Thoracic cancer

authors： Lee HJ,Seon HJ,Choi YD

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information o...

journal_title：Thoracic cancer

authors： Ming Z,Jiang M,Li W,Fan N,Deng W,Zhong Y,Zhang Y,Zhang Q,Yang S

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:The aim of this study was to evaluate the cytotoxic and antitumor activity of spider venom (SV). METHODS:Cell proliferation and cytotoxicity were determined by 3 H-methyl thymidine incorporation ([3 H]-TDR) assay. DNA fragmentation and cell cycle kinetics were analyzed by FACS. In vivo inhibition of tumor s...

journal_title：Thoracic cancer

authors： Gao L,Zhang J,Liu X,Zhao M,Li L,Liu X,Zhao B

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

journal_title：Thoracic cancer

authors： Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：:Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

journal_title：Thoracic cancer

authors： Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

更新日期：2016-03-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

journal_title：Thoracic cancer

authors： Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

journal_title：Thoracic cancer

authors： Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

更新日期：2020-04-01 00:00:00

abstract：:Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

journal_title：Thoracic cancer

authors： Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

更新日期：2015-11-01 00:00:00

abstract：:In recent years, studies have found that E2F1, a downstream effector of caveolin-1 (Cav-1), participates in tumor cell metabolic reprogramming. E2F1 modulates mitochondrial fusion and mitophagy. Bioinformatic analysis has identified the E2F1-MFN2 axis as a regulator of mitophagy. Our data establish a new novel paradig...

journal_title：Thoracic cancer

authors： Shen C,Chen X,Xiao K,Che G

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

journal_title：Thoracic cancer

authors： Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

journal_title：Thoracic cancer

authors： Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

更新日期：2018-05-01 00:00:00